Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19
Dr James J Dinicolantonio, Jorge Barroso, Mark Mccarty
Open Heart, doi:10.1136/openhrt-2020-001350
Author name Jorge Barroso has been corrected to Jorge Barroso-Aranda.
References
Andersson, Ottestad, Tracey, Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?, Mol Med,
doi:10.1186/s10020-020-00172-4Ci, Li, Yu, Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol,
doi:10.1111/j.1472-8206.2009.00684.xGorial, Mashhadani, Sayaly, Effectiveness of ivermectin as add-on therapy in COVID-19 management, medRxiv
Rajter, Sm, Fatteh, Vogel, Icon (ivermectin Ni COvid nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19, medRxiv
Schmith, Zhou, Lohmer, The Approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther,
doi:10.1002/cpt.1889Ventre, Rozières, Lenief, Topical ivermectin improves allergic skin inflammation, Allergy,
doi:10.1111/all.13118Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res,
doi:10.1007/s00011-008-8007-8Zhang, Song, Xiong, Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol,
doi:10.1016/j.intimp.2008.12.016DOI record:
{
"DOI": "10.1136/openhrt-2020-001350",
"ISSN": [
"2053-3624"
],
"URL": "http://dx.doi.org/10.1136/openhrt-2020-001350",
"alternative-id": [
"10.1136/openhrt-2020-001350"
],
"author": [
{
"ORCID": "http://orcid.org/0000-0002-7888-1528",
"affiliation": [],
"authenticated-orcid": false,
"family": "DiNicolantonio",
"given": "James J",
"sequence": "first"
},
{
"affiliation": [],
"family": "Barroso",
"given": "Jorge",
"sequence": "additional"
},
{
"affiliation": [],
"family": "McCarty",
"given": "Mark",
"sequence": "additional"
}
],
"container-title": "Open Heart",
"container-title-short": "Open Heart",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"bmj.com"
]
},
"created": {
"date-parts": [
[
2020,
9,
7
]
],
"date-time": "2020-09-07T07:35:23Z",
"timestamp": 1599464123000
},
"deposited": {
"date-parts": [
[
2020,
9,
26
]
],
"date-time": "2020-09-26T10:50:00Z",
"timestamp": 1601117400000
},
"indexed": {
"date-parts": [
[
2024,
5,
14
]
],
"date-time": "2024-05-14T18:01:48Z",
"timestamp": 1715709708614
},
"is-referenced-by-count": 26,
"issue": "2",
"issued": {
"date-parts": [
[
2020,
9
]
]
},
"journal-issue": {
"issue": "2",
"published-online": {
"date-parts": [
[
2020,
9,
6
]
]
},
"published-print": {
"date-parts": [
[
2020,
9
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by-nc/4.0/",
"content-version": "unspecified",
"delay-in-days": 3,
"start": {
"date-parts": [
[
2020,
9,
4
]
],
"date-time": "2020-09-04T00:00:00Z",
"timestamp": 1599177600000
}
}
],
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1136/openhrt-2020-001350",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "239",
"original-title": [],
"page": "e001350",
"prefix": "10.1136",
"published": {
"date-parts": [
[
2020,
9
]
]
},
"published-online": {
"date-parts": [
[
2020,
9,
6
]
]
},
"published-print": {
"date-parts": [
[
2020,
9
]
]
},
"publisher": "BMJ",
"reference": [
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"author": "Caly",
"doi-asserted-by": "crossref",
"journal-title": "Antiviral Res",
"key": "2020090700350916000_7.2.e001350.1",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.1002/cpt.1889",
"article-title": "The Approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19",
"author": "Schmith",
"doi-asserted-by": "crossref",
"journal-title": "Clin Pharmacol Ther",
"key": "2020090700350916000_7.2.e001350.2",
"year": "2020"
},
{
"DOI": "10.1007/s00011-008-8007-8",
"doi-asserted-by": "publisher",
"key": "2020090700350916000_7.2.e001350.3"
},
{
"DOI": "10.1016/j.intimp.2008.12.016",
"article-title": "Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages",
"author": "Zhang",
"doi-asserted-by": "crossref",
"first-page": "354",
"journal-title": "Int Immunopharmacol",
"key": "2020090700350916000_7.2.e001350.4",
"volume": "9",
"year": "2009"
},
{
"DOI": "10.1890/09-0817.1",
"doi-asserted-by": "publisher",
"key": "2020090700350916000_7.2.e001350.5"
},
{
"DOI": "10.1111/j.1472-8206.2009.00684.x",
"article-title": "Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway",
"author": "Ci",
"doi-asserted-by": "crossref",
"first-page": "449",
"journal-title": "Fundam Clin Pharmacol",
"key": "2020090700350916000_7.2.e001350.6",
"volume": "23",
"year": "2009"
},
{
"DOI": "10.1007/s00011-011-0307-8",
"article-title": "Anti-Inflammatory effects of ivermectin in mouse model of allergic asthma",
"author": "Yan",
"doi-asserted-by": "crossref",
"first-page": "589",
"journal-title": "Inflamm Res",
"key": "2020090700350916000_7.2.e001350.7",
"volume": "60",
"year": "2011"
},
{
"DOI": "10.1111/all.13118",
"article-title": "Topical ivermectin improves allergic skin inflammation",
"author": "Ventre",
"doi-asserted-by": "crossref",
"first-page": "1212",
"journal-title": "Allergy",
"key": "2020090700350916000_7.2.e001350.8",
"volume": "72",
"year": "2017"
},
{
"DOI": "10.1186/s10020-020-00172-4",
"article-title": "Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?",
"author": "Andersson",
"doi-asserted-by": "crossref",
"first-page": "42",
"journal-title": "Mol Med",
"key": "2020090700350916000_7.2.e001350.9",
"volume": "26",
"year": "2020"
},
{
"DOI": "10.1101/2020.06.06.20124461",
"doi-asserted-by": "crossref",
"key": "2020090700350916000_7.2.e001350.10",
"unstructured": "Rajter.J.C. SM , Fatteh N , Vogel F , et al . Icon (ivermectin Ni COvid nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv 2020."
},
{
"DOI": "10.1101/2020.07.07.20145979",
"doi-asserted-by": "crossref",
"key": "2020090700350916000_7.2.e001350.11",
"unstructured": "Gorial FI , Mashhadani S , Sayaly HM , et al . Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). medRxiv 2020."
}
],
"reference-count": 11,
"references-count": 11,
"relation": {},
"resource": {
"primary": {
"URL": "https://openheart.bmj.com/lookup/doi/10.1136/openhrt-2020-001350"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1136/crossmarkpolicy",
"volume": "7"
}
